Funded equally by LUNGevity Foundation and the National Lung Cancer Partnership
Lee Goodglick, PhD
David Geffen School of Medicine at UCLA
Los Angeles
The rationale behind Dr. Goodglick’s research is that the hormone estrogen and estrogen-pathway activation are important for lung cancer progression. Aromatase is an enzyme that makes estrogen in the body. Dr. Goodglick is conducting extensive pre-clinical evaluations of three aromatase inhibitors to understand steps in the estrogen stimulation pathway that affect tumor progression.